Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma.

To determine the potential utility of antigen-specific immune complex analysis, we developed a competitive enzyme-linked immunosorbent assay utilizing polyclonal human antibody to detect tumor-associated antigen-specific immune complexes. Sera from 10 normal volunteers and 19 patients with recurrent melanoma were studied. Patients with recurrent melanoma had a mean +/- SD percent inhibition of 27.6% +/- 29.8% in contrast to normal individuals with a mean value of 8.4% +/- 17.8%. A monoclonal antibody (MAb JSI) was developed following immunization with a partially purified antigen. Utilizing MAb JSI, we developed a "sandwich" enzyme-linked immunosorbent assay and studied sera from 45 normal volunteers and 44 patients with cancer with recurrent melanoma. Results were expressed as a percent maximum binding of a positive control. The mean +/- SD percent maximum binding for normal subjects was 4.9% +/- 7.7% in contrast to sera from patients with melanoma who had a mean of 38.3% +/- 33.3%. Serial analysis of four patients with melanoma with tumor-associated antigen-specific immune complexes demonstrated the presence of tumor-associated antigen-specific immune complexes up to 12 years prior to clinical recurrence.

[1]  R. Gupta,et al.  Serial determinations of melanoma tumor-associated antigen and antibody in patients with stage I melanoma. , 1986, Archives of surgery.

[2]  M. Baseler,et al.  Immune complexes, serum proteins, cell‐mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck , 1986, Cancer.

[3]  A. Cochran,et al.  Recurrence potential of thin primary melanomas , 1986, Cancer.

[4]  J. Kirkwood,et al.  Augmentation of autologous antibody to human melanoma following acid dissociation and ultrafiltration of serum. , 1984, Cancer research.

[5]  R. Gupta,et al.  Immunochemical characterization of fetal antigen isolated from spent medium of a human melanoma cell line. , 1983, Journal of the National Cancer Institute.

[6]  J. Bystryn.  Shedding and Degradation of Cell-Surface Macromolecules and Melanoma-Associated Antigens by Human Melanoma , 1982 .

[7]  P. Hersey,et al.  Evaluation of assays to detect immune complexes as an immunodiagnostic aid in patients with melanoma. , 1982, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[8]  L. Old.  Cancer immunology: the search for specificity. , 1982, National Cancer Institute monograph.

[9]  H. Luthra,et al.  Report on international comparative evaluation of possible value of assays for immune complexes for diagnosis of human breast cancer , 1981, International journal of cancer.

[10]  L. Old.  Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. , 1981, Cancer research.

[11]  P. Black,et al.  Shedding from the cell surface of normal and cancer cells. , 1980, Advances in cancer research.

[12]  A. Breslow.  Prognostic Factors in the Treatment of Cutaneous Melanoma , 1979, Journal of cutaneous pathology.

[13]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[14]  E. Engvall,et al.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. , 1972, Journal of immunology.

[15]  I. Hellstrom,et al.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[16]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.